Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBT: 2017-2024

Historic EBT for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$542.2 million.

  • BridgeBio Pharma's EBT fell 13.53% to -$186.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.5 million, marking a year-over-year decrease of 85.50%. This contributed to the annual value of -$542.2 million for FY2024, which is 17.00% up from last year.
  • As of FY2024, BridgeBio Pharma's EBT stood at -$542.2 million, which was up 17.00% from -$653.3 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's EBT peaked at -$485.1 million during FY2022, and registered a low of -$653.3 million during FY2023.
  • Its 3-year average for EBT is -$560.2 million, with a median of -$542.2 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 75.16% in 2020, then rose by 17.29% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's EBT stood at -$505.5 million in 2020, then decreased by 16.02% to -$586.5 million in 2021, then climbed by 17.29% to -$485.1 million in 2022, then tumbled by 34.67% to -$653.3 million in 2023, then rose by 17.00% to -$542.2 million in 2024.